Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Valneva Austria GmbH is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. The busiest examiner for the portfolio is MORGAN, BAILEY MICHELLE, who is currently handling 1 pending office action.
This distribution indicates that the company's prosecution workload is spread across 3 distinct examiners rather than being concentrated under 1 individual. For the legal team, this requires managing 3 different examiner styles simultaneously. The involvement of 2 distinct art units further suggests a diversification in the technical focus of the pending applications. This variety in examiners and units means that the company must maintain a flexible prosecution strategy.
With 3 pending office actions, the portfolio is active across several fronts. The fact that the busiest examiner only handles 1 pending office action highlights the lack of examiner concentration. Practitioners should be prepared to navigate the specific procedural nuances of 2 distinct art units. This spread of 3 actions across 3 examiners can help mitigate the impact of any 1 examiner's rejection on the overall portfolio. The 2 distinct art units involved require the legal team to stay updated on different sets of internal guidelines.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 34d |
| 17917010 | IMPROVEMENTS IN VACCINE FORMULATIONS FOR MEDICAL USE | MORGAN, BAILEY MICHELLE | — |
| 17932226 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17917010 | IMPROVEMENTS IN VACCINE FORMULATIONS FOR MEDICAL USE | MORGAN, BAILEY MICHELLE | 1645 | §112 | Non-Final OA | — | Pending | Oct 05, 2022 |
| 17932226 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO | DUFFY, PATRICIA ANN | 1645 | DP | Non-Final OA | — | Pending | Sep 14, 2022 |
| 17688960 | INACTIVATION PROCESS FOR VIRUSES | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 34d | Pending | Mar 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial